Anti-TWEAKR/FN14 Mouse mAb

Primary Antibodies

TWEAKR/FN14

Store at -20°C. Avoid freeze/thaw cycles.

CD266, also named as fibroblast growth factor-inducible 14 (Fn14), is a member of the TNF superfamily of receptors and is thought to be involved in cell growth, adhesion and migration. Its expression is regulated by a number of different growth factors. Elevated expression is also seen in some cancers including hepatocellular carcinomas, glioblastomas, and pancreatic cancer. The receptor contains a binding site for members of the TNFR-associated factor (TRAF) family that promotes the activation of NF-κB. Recent studies have suggested some therapeutic potential of CD266 in regards to autoimmunity and cancer treatment.

PBS, Glycerol, BSA

Recombinant Monoclonal

CD266, also named as fibroblast growth factor-inducible 14 (Fn14), is a member of the TNF superfamily of receptors and is thought to be involved in cell growth, adhesion and migration. Its expression is regulated by a number of different growth factors. Elevated expression is also seen in some cancers including hepatocellular carcinomas, glioblastomas, and pancreatic cancer. The receptor contains a binding site for members of the TNFR-associated factor (TRAF) family that promotes the activation of NF-κB. Recent studies have suggested some therapeutic potential of CD266 in regards to autoimmunity and cancer treatment.